Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
16
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFirst quarter of the fiscal year ending March 20276 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥2,557 million+16.0%
Operating profit¥824 100 million +24.0%profit from ordinary operating activities
Ordinary income¥860 100 million +28.0%profit before tax, IFRS
Results for the three months of the current quarter
Revenue
¥2,557 million+16.0%
Profit from ordinary operating activities
¥824 million+24.0%
Profit before tax
¥860 million+28.0%
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD exchange rate
¥160.72
Year on year against the same period last year-11.8%
EUR exchange rate
¥186.13
Year on year against the same period last year-12.7%
New initiatives
- Repurchase of up to ¥200 billion of the company's own shares
- Spin-off of the endoscope business in Japan
- Beginning consideration of a business transfer of the endoscope business to a third party and other strategic options
- Improving capacity utilization at the Laos plant and establishing production capabilities for HAMR substrates and other products
- Renaming the business to Optical Solutions
Key KPIsA metric the company considers important as a management benchmark.
- Eyeglass lens revenue growth16 %
- Contact lens (eyecity) revenue growth3 %
- Endoscope revenue growth8 %
- Intraocular lens revenue growth17 %
- Artificial bone and other revenue growth15 %
- LSI revenue growth21 %
- FPD revenue growth9 %
- HDD substrate revenue growth29 %
- Optical Solutions Sales Growth Rate22 %
- ROIC23.8 %
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Store trafficIncreased
Average Revenue per CustomerHigher
Subscription and Other UsageExpansion
Segment results
Life Care
Revenue
¥154.8 billion+13.0%
Profit from ordinary operating activities
¥29.9 billion+24.0%
Information and Communications
Revenue
¥101 billion+23.0%
Profit from ordinary operating activities
¥55.6 billion+28.0%
Acquisition of treasury shares
Maximum amount
¥2,000 million
Maximum number of shares
1,000 10,000 shares
Survey period2026/08/03〜2027/03/24
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥2,557 million (YoY +16.0%) |
| Operating profit | ¥824 100 million (profit from ordinary operating activities) (YoY +24.0%) |
| Ordinary income | ¥860 100 million (profit before tax, IFRS) (YoY +28.0%) |
| Results for the three months of the current quarter | Revenue ¥2,557 million (YoY +16.0%) / Profit from ordinary operating activities ¥824 million (YoY +24.0%) / Profit before tax ¥860 million (YoY +28.0%) |
| Segment results | Life Care Revenue ¥154.8 billion (YoY +13.0%) / Profit from ordinary operating activities ¥29.9 billion (YoY +24.0%) / Information and Communications Revenue ¥101 billion (YoY +23.0%) / Profit from ordinary operating activities ¥55.6 billion (YoY +28.0%) |
| Key KPIs | Indicator name Eyeglass lens revenue growth / Value 16 % / Year on year against the same period last year Not disclosed, Indicator name Contact lens (eyecity) revenue growth / Value 3 % / Year on year against the same period last year Not disclosed, Indicator name Endoscope revenue growth / Value 8 % / Year on year against the same period last year Not disclosed, Indicator name Intraocular lens revenue growth / Value 17 % / Year on year against the same period last year Not disclosed, Indicator name Artificial bone and other revenue growth / Value 15 % / Year on year against the same period last year Not disclosed, Indicator name LSI revenue growth / Value 21 % / Year on year against the same period last year Not disclosed, Indicator name FPD revenue growth / Value 9 % / Year on year against the same period last year Not disclosed, Indicator name HDD substrate revenue growth / Value 29 % / Year on year against the same period last year Not disclosed, Indicator name Optical Solutions Sales Growth Rate / Value 22 % / Year on year against the same period last year Not disclosed, Indicator name ROIC / Value 23.8 % / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | Store traffic Increased / Average Revenue per Customer Higher / Subscription and Other Usage Expansion |
| Assumptions Underlying the Business Outlook | USD exchange rate ¥160.72 / EUR exchange rate ¥186.13 |
| Acquisition of treasury shares | Maximum amount ¥2,000 million / Maximum number of shares 1,000 10,000 shares / Survey period 2026/08/03〜2027/03/24 |
| New initiatives | Repurchase of up to ¥200 billion of the company's own shares, Spin-off of the endoscope business in Japan, Beginning consideration of a business transfer of the endoscope business to a third party and other strategic options, Improving capacity utilization at the Laos plant and establishing production capabilities for HAMR substrates and other products, Renaming the business to Optical Solutions |
Items this document does not state (19)
Net incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The reasons cited include steady performance in both the Life Care Business and the Information & Communication Business, the impact of higher revenue, a greater mix of high-value-added products, continued cost rationalization, demand related to AI, and data center investment.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.